Amanta Healthcare Limited held its Q1 FY27 earnings conference call on August 6, 2026. The call was attended by Mr. Bhavesh Patel, Chairman and Managing Director, and Mr. Paras Mehta, Chief Financial Officer. The discussion included forward-looking statements subject to business risks.

Financial Performance

  • Q1 FY27 revenue was ₹69 crore, representing a 5% year-on-year growth
  • EBITDA for the quarter was approximately ₹15 crore
  • EBITDA margin remained healthy at 22%
  • Performance was achieved despite inflationary pressures and higher operating costs
  • Cost pressures were noted from raw material price increases, employee costs, and other operating expenses related to new facilities

Capacity Expansion Updates

SteriPort Platform
  • Currently contributes approximately 44% of company revenue
  • Capacity expansion from 6.6 crore bottles per year to 12 crore bottles per year
  • Original target commissioning was Q1 FY27 but delayed due to civil construction activities
  • FDA plans approved on August 4, 2026
  • Validation and qualification activities expected to complete by August 18, 2026
  • Commercial production targeted for late August 2026
  • Expected annualized revenue contribution: ₹110-120 crore
  • Expected incremental annual depreciation: ₹4.5 crore from this line
Small Volume Parenteral (SVP) Business
  • Contributed approximately 20% of FY26 revenue
  • Primarily export-centric business addressing inhalation solutions, ophthalmics, and preservative-free unit doses
  • New facility expected to commence operations during Q4 FY27 (February-March 2027)
  • Factory Acceptance Test (FAT) scheduled in USA in second week of November 2026
  • 20 products in development pipeline
  • First inhalation product expected to be commercialized by mid-September 2026

Cost Optimization Initiatives

  • 10.8 megawatt captive solar power project commissioned in June 2026
  • Expected to reduce power costs significantly (approximately ₹9 crore annual savings)
  • Expected to improve operating margins and strengthen ESG initiatives

Raw Material Price Pressures

  • Polymer prices increased by 70-80% during the quarter due to Middle Eastern crisis
  • Price spike lasted approximately 2-2.5 months
  • Company increased selling prices by approximately ₹1.50 per unit to mitigate impact
  • Polymer prices have since softened and are expected to normalize within 2-3 months

Financial Guidance

FY27 Expectations
  • Revenue guidance: Approximately ₹370 crore (excluding SVP contribution)
  • SteriPort Line 3 expected to contribute approximately ₹70 crore in remaining 7 months of FY27
  • Total annual depreciation increase: ₹6 crore (including SteriPort Line 3, SVP facility, and solar plant)
FY28 Expectations
  • Revenue guidance: Approximately ₹425 crore at peak utilization
  • EBITDA guidance: Approximately ₹116 crore
  • EBITDA margin guidance: 25-26%
  • Annual interest cost expected to reduce to ₹18-19 crore

Capital Expenditure

  • SteriPort Line 3: Total capex ₹90 crore (₹80 crore already spent)
  • SVP facility: Total capex ₹30 crore (₹7 crore already spent)

Debt and Working Capital

  • Debt-to-equity ratio: 1.06 (FY26)
  • Working capital days: 141 (FY26)
  • Debt expected to reduce by ₹30-35 crore annually
  • Working capital cycle constrained by 15-30 day quarantine requirements for export products

Growth Strategy

  • Focus on sterile dosage forms
  • Expansion into regulated markets (UK, Ireland, Australia, Canada)
  • Development of inhalation portfolio for hospital market
  • Exploration of other packaging materials beyond plastic (glass)
  • Potential future expansion into other sterile dosage forms (IV bags, injectables, lyophilized products, cartridges)

Research & Development

  • Team of 5 scientists working on 20 products
  • Planning to expand to 8-10 people in F&D and 3-4 people in regulatory affairs
  • Separate formulation development center under construction

Competitive Landscape

  • Main competitors in SteriPort category: Otsuka (Japanese MNC), Fresenius Kabi (German MNC), B. Braun, Aculife
  • SteriPort classified as plastic container with special features per government classification

Tax Rate

  • Effective tax rate: 26%